TerminatedNCT00687609
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
Medication studyAges 13–17Netherlands
Understand this study
Who could participate?
This study is for people with ADHD. Listed age limits: 13 years to 17 years. Other eligibility criteria apply.
- Listed locations
- The HagueSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateSeptember 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 7
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Netherlands
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT00687609
- Official title
Show the full official title
An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.
Recruitment & locations
TerminatedThe Hague
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including Atomoxetine.
Who can participate?
This study is for people with ADHD. Listed age limits: 13 years to 17 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse